Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (349)

« Back to Publications

Erratum to "2025 Focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias" [Atherosclerosis, 409, (October 2025), 120479].

Mach F. et al, (2026), Atherosclerosis, 415

Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY.

Malijan GB. et al, (2026), Am J Kidney Dis, 87, 553 - 563.e1

Pharmacological blood pressure-lowering for prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual participant data meta-analysis of 46 randomised controlled trials

Nazarzadeh M. et al, (2026), The Lancet

Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials

REITH C. et al, (2026), The Lancet

Estimating the long-term effects of aspirin for primary prevention.

Baigent C. et al, (2025), Eur Heart J, 46, 4423 - 4425

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.

Mach F. et al, (2025), Eur Heart J, 46, 4359 - 4378

Effects Of Empagliflozin On Kidney And Cardiac Magnetic Resonance Imaging Measures In Patients With Chronic Kidney Disease: An EMPA-KIDNEY Mechanistic Substudy

ZHU D. et al, (2025), American Journal of Kidney Diseases

[2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias].

Mach F. et al, (2025), G Ital Cardiol (Rome), 26, e1 - e20

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.

Mach F. et al, (2025), Atherosclerosis, 409

Glucose interference in urine biomarkers and implications for SGLT2 inhibition

Malijan GB. et al, (2025), Kidney International Reports

Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence.

Baigent C. and Sádaba R., (2025), Eur Heart J, 46, 3151 - 3153

Individual Participant Level Meta-Analysis Of The Effects Of Empagliflozin On Conventional And Exploratory Acute And Chronic Kidney Outcomes

HERRINGTON W. et al, (2025), The Lancet Diabetes and Endocrinology

Balancing the risk of major bleeding against vascular disease risk in people without atherosclerotic disease.

Hammami I. et al, (2025), Heart, 111, 716 - 721

Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial

Zhou J. et al, (2025), EClinicalMedicine

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.

Judge PK. et al, (2025), Nephrol Dial Transplant, 40, 1175 - 1186

Load More

1
2
3
4
5
6
7
...
»